drugset
drugset / Trial / NCT07039578

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

NCT07039578 ↗

Phase 2 Recruiting 90 enrolled Keymed Biosciences Co.Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis

Timeline

Start
2025-07-25
Primary completion
2026-06-30
Completion
2029-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CM336 Monoclonal antibody — Subcutaneous

Indications

AL amyloidosis